|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Cortex Biochem, Inc. And Bouty S.p.A. Sign Exclusive Distribution Agreement; Bouty To Market Cortex Biochem Inc.'s MagaZorb Nucleic Acid Isolation Kits In Italy
10/19/2005 5:08:54 PM
RALEIGH, N.C.--(BUSINESS WIRE)--June 14, 2005--Cortex Biochem(TM) Inc., a global leader in developing magnetic particle technology and products used in genomic research and clinical diagnostics, has established an exclusive distribution and limited license agreement with Bouty S.p.A. of Milan, Italy. Effective January of this year, the agreement allows Bouty and Bouty's subsidiary Biotechnology Division, Technogenetics S.r.l., to promote, market and sell Cortex Biochem(TM) Inc.'s MagaZorb(R) Nucleic Acid Isolation Kits and associated reagents in Italy.
"We are very excited about our agreement with Bouty, which launches our selling efforts of MagaZorb(R) in Europe," said Matt Pourfarzaneh, President and CEO of Cortex Biochem(TM) Inc. "We are confident that this is the ideal partnership to firmly establish our technology in the European market. We anticipate progressive market penetration since MagaZorb(R) provides greater value with better performing, faster, flexible nucleic acid isolation.
|
|
|
|
|
|
|
|
|
|
|